JP2003502008A5 - - Google Patents

Download PDF

Info

Publication number
JP2003502008A5
JP2003502008A5 JP2000563814A JP2000563814A JP2003502008A5 JP 2003502008 A5 JP2003502008 A5 JP 2003502008A5 JP 2000563814 A JP2000563814 A JP 2000563814A JP 2000563814 A JP2000563814 A JP 2000563814A JP 2003502008 A5 JP2003502008 A5 JP 2003502008A5
Authority
JP
Japan
Prior art keywords
virus
gene
functional
virus according
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2000563814A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003502008A (ja
JP4430824B2 (ja
Filing date
Publication date
Priority claimed from GBGB9816781.0A external-priority patent/GB9816781D0/en
Application filed filed Critical
Publication of JP2003502008A publication Critical patent/JP2003502008A/ja
Publication of JP2003502008A5 publication Critical patent/JP2003502008A5/ja
Application granted granted Critical
Publication of JP4430824B2 publication Critical patent/JP4430824B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

JP2000563814A 1998-07-31 1999-08-02 樹状細胞のためのヘルペスウイルスベクター Expired - Lifetime JP4430824B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9816781.0 1998-07-31
GBGB9816781.0A GB9816781D0 (en) 1998-07-31 1998-07-31 Herpes virus vectors for dendritic cells
PCT/GB1999/002529 WO2000008191A2 (en) 1998-07-31 1999-08-02 Herpes virus vectors for dendritic cells

Publications (3)

Publication Number Publication Date
JP2003502008A JP2003502008A (ja) 2003-01-21
JP2003502008A5 true JP2003502008A5 (https=) 2006-09-14
JP4430824B2 JP4430824B2 (ja) 2010-03-10

Family

ID=10836553

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000563814A Expired - Lifetime JP4430824B2 (ja) 1998-07-31 1999-08-02 樹状細胞のためのヘルペスウイルスベクター

Country Status (17)

Country Link
US (2) US6641817B1 (https=)
EP (1) EP1100942B1 (https=)
JP (1) JP4430824B2 (https=)
KR (1) KR100635246B1 (https=)
CN (1) CN1384884B (https=)
AT (1) ATE374829T1 (https=)
AU (1) AU765105B2 (https=)
BR (1) BR9912653A (https=)
CA (1) CA2337494C (https=)
CY (1) CY1107844T1 (https=)
DE (1) DE69937239T2 (https=)
DK (1) DK1100942T3 (https=)
ES (1) ES2294848T3 (https=)
GB (2) GB9816781D0 (https=)
IL (1) IL141126A0 (https=)
PT (1) PT1100942E (https=)
WO (1) WO2000008191A2 (https=)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1068296B1 (en) 1998-03-31 2011-08-10 Geron Corporation Compositions for eliciting an immune response to a telomerase antigen
US7402307B2 (en) 1998-03-31 2008-07-22 Geron Corporation Method for identifying and killing cancer cells
US6713067B2 (en) 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
GB0009079D0 (en) * 2000-04-12 2000-05-31 Neurovex Ltd Herpes viruses for immune modulation
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
GB2375113B (en) * 2000-01-21 2004-10-20 Biovex Ltd A modified, oncolytic, non-laboratory HSV strain and its use in treating cancer
US7063851B2 (en) 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation
EP1406668A1 (en) * 2001-05-02 2004-04-14 Ramot at Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
EP2213300B1 (en) * 2001-05-09 2015-03-25 Takara Bio, Inc. Composition and method for treating cancer using herpes virus
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
JP2004099584A (ja) * 2002-05-02 2004-04-02 Keio Gijuku Ｈｓｖを用いた抗腫瘍剤
US8216564B2 (en) 2002-05-02 2012-07-10 Ramot At Tel-Aviv University Ltd. Composite oncolytic herpes virus vectors
CA2421269A1 (en) 2002-08-09 2004-02-09 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
GB0317511D0 (en) * 2003-07-25 2003-08-27 Biovex Ltd Viral vectors
WO2007016239A2 (en) * 2005-07-29 2007-02-08 President And Fellows Of Harvard College Herpes simplex virus mutant and uses therefore
KR100878017B1 (ko) * 2007-04-09 2009-01-14 인제대학교 산학협력단 이종 유전자 발현을 위한 숙주균 및 그의 이용방법
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
US9487756B2 (en) 2009-03-20 2016-11-08 Mesoblast, Inc. Production of reprogrammed pluripotent cells
JP2013517772A (ja) 2010-01-21 2013-05-20 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド 遺伝子発見および標的確認を補助するための状況特異的遺伝子スクリーニングプラットフォーム
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
CA2848368C (en) 2011-09-13 2023-02-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using fndc5
US10378060B2 (en) 2011-10-14 2019-08-13 Dana-Farber Cancer Institute, Inc. ZNF365/ZFP365 biomarker predictive of anti-cancer response
EP3134546A4 (en) 2014-04-24 2017-12-06 Dana-Farber Cancer Institute, Inc. Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response
CA2963091A1 (en) 2014-10-06 2016-04-14 Dana-Farber Cancer Institute, Inc. Angiopoietin-2 biomarkers predictive of anti-immune checkpoint response
WO2016057651A1 (en) 2014-10-09 2016-04-14 Dana-Farber Cancer Institute, Inc. Multiple-variable il-2 dose regimen for treating immune disorders
WO2016144673A1 (en) 2015-03-06 2016-09-15 Dana-Farber Cancer Institute, Inc. Pd-l2 biomarkers predictive of pd-1 pathway inhibitor responses in esophagogastric cancers
CN105219738A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
US11207393B2 (en) 2015-10-16 2021-12-28 President And Fellows Of Harvard College Regulatory T cell PD-1 modulation for regulating T cell effector immune responses
AU2016343978A1 (en) 2015-10-29 2018-05-17 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids
WO2017165412A2 (en) 2016-03-21 2017-09-28 Dana-Farber Cancer Institute, Inc. T-cell exhaustion state-specific gene expression regulators and uses thereof
ES3033182T3 (en) 2016-09-20 2025-07-31 Dana Farber Cancer Inst Inc Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
US11820822B2 (en) 2017-06-06 2023-11-21 Dana-Farber Cancer Institute, Inc. Methods for sensitizing cancer cells to T cell-mediated killing by modulating molecular pathways
WO2019168897A2 (en) 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
EA202092165A1 (ru) * 2018-03-19 2021-02-25 Бёрингер Ингельхайм Ветмедика Гмбх Новый ehv сайт инсерции ul43
JP7429192B2 (ja) 2018-04-06 2024-02-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｈｈｌａ２受容体としてのｋｉｒ３ｄｌ３、抗ｈｈｌａ２抗体、およびその使用
EP3962529A4 (en) 2019-04-30 2023-11-01 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
EP4093513A4 (en) 2020-01-24 2024-05-08 Dana-Farber Cancer Institute, Inc. Uses of biomarkers for improving immunotherapy
EP4343004A3 (en) 2020-10-19 2024-09-11 Dana-Farber Cancer Institute, Inc. Germline biomarkers of clinical response and benefit to immune checkpoint inhibitor therapy
WO2022104104A2 (en) 2020-11-13 2022-05-19 Dana-Farber Cancer Institute, Inc. Personalized fusion cell vaccines
CA3207359A1 (en) 2021-02-05 2022-08-11 Cecile Chartier-Courtaud Adjuvant therapy for cancer
US20240280561A1 (en) 2021-06-08 2024-08-22 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
WO2023097119A2 (en) 2021-11-29 2023-06-01 Dana-Farber Cancer Institute, Inc. Methods and compositions to modulate riok2
EP4479080A1 (en) 2022-02-16 2024-12-25 Dana-Farber Cancer Institute, Inc. Methods for decreasing pathologic alpha-synuclein using agents that modulate fndc5 or biologically active fragments thereof
WO2025034542A1 (en) 2023-08-04 2025-02-13 Cornell University Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994003207A1 (en) * 1992-07-31 1994-02-17 President And Fellows Of Harvard College Herpesvirus vaccines
GB9615794D0 (en) * 1996-07-26 1996-09-04 Medical Res Council Mutant herpes simplex virus strains and uses thereof
US5998174A (en) * 1997-05-12 1999-12-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Multigene vectors
US6713067B2 (en) * 1998-07-31 2004-03-30 Biovex Limited Herpes viruses for immune modulation
GB9816781D0 (en) * 1998-07-31 1998-09-30 Univ London Herpes virus vectors for dendritic cells
US7063851B2 (en) * 2000-04-12 2006-06-20 Biovex Limited Herpes viruses for immune modulation

Similar Documents

Publication Publication Date Title
JP2003502008A5 (https=)
JP2003520044A5 (https=)
Bonneau et al. Modulation of acute and latent herpes simplex virus infection in C57BL/6 mice by adoptive transfer of immune lymphocytes with cytolytic activity
Ma et al. Oncolytic herpes simplex virus and immunotherapy
Skoberne et al. An adjuvanted herpes simplex virus 2 subunit vaccine elicits a T cell response in mice and is an effective therapeutic vaccine in Guinea pigs
Su et al. An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application
CN115820571B (zh) 一种重组单纯疱疹病毒及其用途
Koelle et al. Recent progress in herpes simplex virus immunobiology and vaccine research
Leib et al. Interferons regulate the phenotype of wild-type and mutant herpes simplex viruses in vivo
Bai et al. A review of HSV pathogenesis, vaccine development, and advanced applications
CA2398335A1 (en) Herpes virus strains
Whitley et al. Herpes simplex viruses: is a vaccine tenable?
Truong et al. Mechanisms of immune control of mucosal HSV infection: A guide to rational vaccine design
Dobbs et al. Clearance of herpes simplex virus type 2 by CD8+ T cells requires gamma interferon and either perforin-or Fas-mediated cytolytic mechanisms
WO2006002394A3 (en) Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
CA2533338A1 (en) Viral vectors
JP2003520789A5 (https=)
Wildy et al. The host response to herpes simplex virus
Pourchet et al. CD8+ T-cell immune evasion enables oncolytic virus immunotherapy
Nash T cells and the regulation of herpes simplex virus latency and reactivation
JP2003530369A5 (https=)
Matundan et al. Interrelationship of primary virus replication, level of latency, and time to reactivation in the trigeminal ganglia of latently infected mice
Deshpande et al. Why do we lack an effective vaccine against herpes simplex virus infections?
Liu et al. Selective editing of herpes simplex virus 1 enables interferon induction and viral replication that destroy malignant cells
CA2405458A1 (en) Herpes viruses for immune modulation